Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 4
2006 4
2008 4
2009 8
2010 6
2011 5
2012 7
2013 6
2014 6
2015 1
2017 1
2018 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M. de Rosa F, et al. Among authors: ridolfi r. Melanoma Res. 2017 Aug;27(4):351-357. doi: 10.1097/CMR.0000000000000356. Melanoma Res. 2017. PMID: 28654547
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, Parisi E, Romeo A, Guidoboni M. Ridolfi L, et al. Among authors: ridolfi r. J Transl Med. 2014 Sep 23;12:262. doi: 10.1186/s12967-014-0262-6. J Transl Med. 2014. PMID: 25245327 Free PMC article. Clinical Trial.
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. de Rosa F, et al. Among authors: ridolfi r. J Transl Med. 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209. J Transl Med. 2014. PMID: 25053129 Free PMC article. Clinical Trial.
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P. Ascierto PA, et al. Among authors: ridolfi r. J Transl Med. 2014 May 7;12:116. doi: 10.1186/1479-5876-12-116. J Transl Med. 2014. PMID: 24885479 Free PMC article.
MicroRNAs and dendritic cell-based vaccination in melanoma patients.
de Rosa F, Fanini F, Guidoboni M, Vannini I, Amadori D, Ridolfi R, Ridolfi L, Fabbri M. de Rosa F, et al. Among authors: ridolfi r. Melanoma Res. 2014 Jun;24(3):181-9. doi: 10.1097/CMR.0000000000000058. Melanoma Res. 2014. PMID: 24638153 Review.
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Ascierto PA, et al. Among authors: ridolfi r. Cancer Invest. 2014 May;32(4):144-9. doi: 10.3109/07357907.2014.885984. Epub 2014 Jan 31. Cancer Invest. 2014. PMID: 24484235
55 results